

IFM PUBLICATIONS 2016

1. Serum free light chains, not urine specimens, should be used to evaluate response in light-chain **multiple myeloma**.
Dejoie T, Corre J, Caillon H, Hulin C, Perrot A, Caillot D, Boyle E, Chretien ML, Fontan J, Belhadj K, Brechignac S, Decaux O, Voillat L, Rodon P, Fitoussi O, Araujo C, Benboubker L, Fontan C, Tiab M, Godmer P, Luycx O, Allangba O, Pignon JM, Fuzibet JG, Legros L, Stoppa AM, Dib M, Pegourie B, Orsini-Piocelle F, Karlin L, Arnulf B, Roussel M, Garderet L, Mohty M, Meuleman N, Doyen C, Lenain P, Macro M, Leleu X, Facon T, Moreau P, Attal M, Avet-Loiseau H. *Blood*. 2016 Dec 22;128(25):2941-2948. doi: 10.1182/blood-2016-07-726778. Epub 2016 Oct 11.
2. IFM (Intergroupe francophone du myélome) recommendations for uniform interpretation of serum and urine protein electrophoresis in **multiple myeloma** diagnosis and follow-up.
Dejoie T, Lakomy D, Caillon H, Pegourié B, Decaux O. *Ann Biol Clin (Paris)*. 2016 Aug 1;74(4):429-41. doi: 10.1684/abc.2016.1166.
3. A Genome-Wide Association Study Identifies a Novel Locus for Bortezomib-Induced Peripheral Neuropathy in European Patients with **Multiple Myeloma**.
Magrangeas F, Kuiper R, Avet-Loiseau H, Gouraud W, Guérin-Charbonnel C, Ferrer L, Aussem A, Elghazel H, Suhard J, Der Sakissian H, Attal M, Munshi NC, Sonneveld P, Dumontet C, Moreau P, van Duin M, Campion L, Minvielle S. *Clin Cancer Res*. 2016 Sep 1;22(17):4350-5. doi: 10.1158/1078-0432.CCR-15-3163. Epub 2016 Apr 8.
4. Safe and prolonged survival with long-term exposure to pomalidomide in relapsed/refractory **myeloma**.
Fouquet G, Pegourie B, Macro M, Petillon MO, Karlin L, Caillot D, Roussel M, Arnulf B, Mathiot C, Marit G, Kolb B, Stoppa AM, Brechiniac S, Richez V, Rodon P, Banos A, Wetterwald M, Garderet L, Royer B, Hulin C, Benboubker L, Decaux O, Escoffre-Barbe M, Femand JP, Attal M, Avet-Loiseau H, Moreau P, Facon T, Leleu X; IFM (Intergroupe Francophone du Myélome). *Ann Oncol*. 2016 May;27(5):902-7. doi: 10.1093/annonc/mdw017. Epub 2016 Jan 19.